These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30602032)

  • 1. Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study.
    Ishiguro N; Tanaka Y; Yamanaka H; Yoneda T; Ohira T; Okubo N; Genant HK; van der Heijde D; Takeuchi T
    Rheumatology (Oxford); 2019 Jun; 58(6):997-1005. PubMed ID: 30602032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial.
    Takeuchi T; Tanaka Y; Ishiguro N; Yamanaka H; Yoneda T; Ohira T; Okubo N; Genant HK; van der Heijde D
    Ann Rheum Dis; 2016 Jun; 75(6):983-90. PubMed ID: 26585988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction.
    Tanaka Y; Soen S; Ishiguro N; Yamanaka H; Yoneda T; Tanaka S; Ohira T; Nitta T; Okubo N; Genant H; van der Heijde D; Takeuchi T
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32732353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of the inhibitory effect on bone erosion progression with denosumab treatment and conventional treatment in rheumatoid arthritis patients: study protocol for an open-label randomized controlled trial by HR-pQCT.
    Iwamoto N; Sato S; Sumiyoshi R; Chiba K; Miyamoto N; Arinaga K; Kobayashi M; Yamamoto H; Osaki M; Kawakami A
    Trials; 2019 Aug; 20(1):494. PubMed ID: 31409388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies.
    Takeuchi T; Soen S; Ishiguro N; Yamanaka H; Tanaka S; Kobayashi M; Okubo N; Nitta T; Tanaka Y
    Mod Rheumatol; 2021 Jan; 31(1):34-41. PubMed ID: 31826682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.
    Cohen SB; Dore RK; Lane NE; Ory PA; Peterfy CG; Sharp JT; van der Heijde D; Zhou L; Tsuji W; Newmark R;
    Arthritis Rheum; 2008 May; 58(5):1299-309. PubMed ID: 18438830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Takeuchi T; Tanaka Y; Soen S; Yamanaka H; Yoneda T; Tanaka S; Nitta T; Okubo N; Genant HK; van der Heijde D
    Ann Rheum Dis; 2019 Jul; 78(7):899-907. PubMed ID: 31036625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis.
    Ebina K; Hirao M; Hashimoto J; Matsuoka H; Iwahashi T; Chijimatsu R; Etani Y; Okamura G; Miyama A; Yoshikawa H
    Osteoporos Int; 2018 Jul; 29(7):1627-1636. PubMed ID: 29574517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
    Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
    Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study.
    Tanaka Y; Takeuchi T; Soen S; Yamanaka H; Yoneda T; Tanaka S; Nitta T; Okubo N; Genant HK; van der Heijde D
    J Rheumatol; 2021 Nov; 48(11):1663-1671. PubMed ID: 33858976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of denosumab switched from bisphosphonates in preventing joint destruction in postmenopausal rheumatoid arthritis patients with anti-cyclic citrullinated peptide antibodies.
    Mori Y; Izumiyama T; Kurishima H; Kamimura M; Baba K; Mori N; Itoi E
    J Orthop Surg Res; 2021 Feb; 16(1):107. PubMed ID: 33541393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis.
    Katchamart W; Koolvisoot A; Aromdee E; Chiowchanwesawakit P; Muengchan C
    Rheumatol Int; 2015 Oct; 35(10):1693-9. PubMed ID: 25903353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients.
    Deodhar A; Dore RK; Mandel D; Schechtman J; Shergy W; Trapp R; Ory PA; Peterfy CG; Fuerst T; Wang H; Zhou L; Tsuji W; Newmark R
    Arthritis Care Res (Hoboken); 2010 Apr; 62(4):569-74. PubMed ID: 20391513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y; Suzuki T; Kato H
    Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial.
    So H; Cheng IT; Lau SL; Chow E; Lam T; Hung VW; Li EK; Griffith JF; Lee VW; Shi L; Huang J; Kwok KY; Yim CW; Li TK; Lo V; Lee J; Lee JJ; Qin L; Tam LS
    Ann Rheum Dis; 2021 Aug; 80(8):981-988. PubMed ID: 33811034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
    de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Verpoort KN; Schreuder GM; Ewals JA; Terwiel JP; Ronday HK; Kerstens PJ; Toes RE; de Vries RR; Breedveld FC; Dijkmans BA; Huizinga TW; Allaart CF
    Arthritis Rheum; 2008 May; 58(5):1293-8. PubMed ID: 18438829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of serum bone-related minerals during denosumab treatment in osteoporosis patients with rheumatoid arthritis: Mineral change by denosumab in osteoporosis with rheumatoid arthritis.
    Suzuki T; Nakamura Y; Kato H
    Clin Nutr ESPEN; 2018 Aug; 26():53-56. PubMed ID: 29908683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Efficacy of Denosumab in Patients With Rheumatoid Arthritis: A Systematic Review and Pooled Analysis of Randomized or Matched Data.
    Hu Q; Zhong X; Tian H; Liao P
    Front Immunol; 2021; 12():799575. PubMed ID: 35069583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of denosumab in Japanese patients with rheumatoid arthritis: A 2-year post-marketing surveillance study.
    Tanaka Y; Mizutani H; Fujii K; Okubo N
    Mod Rheumatol; 2024 Aug; 34(5):927-935. PubMed ID: 38048431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repair of Bone Erosion in Rheumatoid Arthritis by Denosumab: A High-Resolution Peripheral Quantitative Computed Tomography Study.
    Yue J; Griffith JF; Xiao F; Shi L; Wang D; Shen J; Wong P; Li EK; Li M; Li TK; Zhu TY; Hung VW; Qin L; Tam LS
    Arthritis Care Res (Hoboken); 2017 Aug; 69(8):1156-1163. PubMed ID: 27768831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.